|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Cyclosporin a in the treatment of myelodysplastic syndromes (mds)статья Тезисы
- Авторы: Shirin A.D., Volkova M.A.
- Журнал: European Journal of Cancer
- Том: 33
- Номер: S58
- Год издания: 1997
- Издательство: Pergamon Press Ltd.
- Местоположение издательства: United Kingdom
- Первая страница: S95
- Последняя страница: S95
- DOI: 10.1016/s0959-8049(97)84863-0
- Аннотация: Purpose: Enhanced apoptosis is considered one of the main causes of cytopenia in MDS. Since Cyclosporin A (CyA) is known as an inhibitor of the apoptosis some authors used CyA for treatment of MDS patients (pts) with certain success. The aim of this study was to evaluate the efficiency of the CyA in the MDS treatment.Methods: 8 pts with MDS (3 RA, 3 RAEB, 1 RAEBt and 1 CMML) in age from 16 to 67 years (median age - 50) received oral CyA in following doses: 10 mg/kg for the first 10 days, then 5 mg/kg for all period of the treatment (1-9 months). During the treatment the CyA level in blood was not more than 340 ng/ml.Results: A positive effect was achieved in 7 pts: in 6 cases PLT count increased, RBC-transfusion requirements decreased in 3 of 6 transfusion-dependent pts, WBC count increased in 3 of 6 pts with leukopenia. In one case there was a reductions of blast cells in bone marrow from 11% to 5%. The duration of positive effect was no longer than 6 months. Two pts (one with RAEB and one with RAEBt) developed progressive disease to frank AML.Conclusion: The treatment of MDS pts with CyA can be successful but improvement is transient.
- Добавил в систему: Ширин Антон Дмитриевич